Citius OncologyCTOR
13F holders, Q1 2025 (March 31)6holders −5
0new positions
5sold out
$0.93avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Citius Oncology Inc. (CTOR) in their 13F filings, down 5 from Q4 2024. 0 opened new positions and 5 sold out. The largest holders were UBS Group AG ($46K), IFP Advisors, Inc ($21K) and Geode Capital Management, LLC ($19K).
- Company
- Citius Oncology Inc.
- CUSIP
- 17331Y109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $141K |
All 13F filers, Q4 2024 → Q1 2025: 32,828 shares bought and 128,704 shares sold, net −95,876 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +100.5% | 49,745 | $46K |
| IFP Advisors, Inc | 0.00% | No change | 22,215 | $21K |
| Geode Capital Management, LLC | 0.00% | Add +62.4% | 20,539 | $19K |
| Yakira Capital Management, Inc. | 0.00% | No change | 11,999 | $11K |
| Osaic Holdings, Inc. | 0.00% | Reduce -93.6% | 350 | $325 |
| Bank of America Corp. | 0.00% | No change | 160 | $149 |
"% of holder's portfolio" is CTOR's weight in each manager's 13F, not the share of Citius Oncology Inc. the manager owns.